Last reviewed · How we verify
Pegylated interferon alfa 2b
At a glance
| Generic name | Pegylated interferon alfa 2b |
|---|---|
| Also known as | PegInteron |
| Sponsor | Kirby Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (PHASE2)
- Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B (PHASE4)
- Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply (PHASE2)
- Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients (PHASE4)
- Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated interferon alfa 2b CI brief — competitive landscape report
- Pegylated interferon alfa 2b updates RSS · CI watch RSS
- Kirby Institute portfolio CI